Földi indicated that TKTL1 expression in 86% of breast cancer specimens with 45% showing high expression levels. Langbein[13] demonstrated that Transketolase was more elevated in metastasizing renal cell cancer and TKTL1 protein was significantly overexpressed in progressing renal cell cancer. Our previous study revealed that TKTL1 play an important role in cell proliferation of colon cancer, hepatoma and nasopharyngeal carcinoma [14–16]. These results indicated that TKTL1 could be seen as a potential target for novel anti-transketolase cancer therapies. In a word, TKTL1 plays an important role in total transketolase activity and proliferation of tumor

cells in uterine cervix cancer. After the expression click here of TKTL1 was silenced, the proliferation of uterine cervix cancer cells was significantly inhibited; there was no significant change in normal cervical epithelial cells. We think that the most effective way to inhibit tumor proliferation

should be to block the generation of energy or nucleic acids for tumor growth. So, we believe TKTL1 gene might become a novel hot spot of study in anticancer therapy. References 1. Garber K: Energy deregulation: Licensing Berzosertib manufacturer tumor to grow. Science 2006, 312: 1158–9.CrossRefhttps://www.selleckchem.com/products/selonsertib-gs-4997.html PubMed 2. Warburg O, Posener K, Negelein EL: Uber den Stoffwechsel der Carcinomzelle. Biochem Z 1924, 152: 309–44. 3. Downey Flavopiridol (Alvocidib) RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, Rusch V: Preoperative F-18 fluorodeoxyglucose-positron emission tomography

maximal standardized uptake value pre-dicts survival after lung cancer resection. J Clin Oncol 2004, 22: 3255–60.CrossRefPubMed 4. Boros LG, Puigjaner J, Cascante M, Lee WN, Brandes JL, Bassilian S, Yusuf FI, Williams RD, Muscarella P, Melvin WS, Schirmer WJ: Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 1997, 57: 4242–8.PubMed 5. Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N, Popa J, Ternullo MP, Steidler A, Weiss C, Grobholz R, Willeke F, Alken P, Stassi G, Schubert P, Coy JF: Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 2006, 94: 578–85.CrossRefPubMed 6. Staiger WI, Coy JF, Grobholz R, Hofheinz RD, Lukan N, Post S, Schwarzbach MH, Willeke F: Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep 2006, 16: 657–61.PubMed 7. Kohrenhagen N, Voelker HU, Schmidt M, Kapp M, Krockenberger M, Frambach T, Dietl J, Kammerer U: Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia. J Obstet Gynaecol Res 2008, 34: 293–300.CrossRefPubMed 8.